Department of Cardiology Tel Aviv Sourasky Medical Center and Sackler School of MedicineTel Aviv University Tel Aviv Israel.
Department of Intensive Care Tel Aviv Sourasky Medical Center and Sackler School of MedicineTel Aviv University Tel Aviv Israel.
J Am Heart Assoc. 2022 Apr 5;11(7):e024363. doi: 10.1161/JAHA.121.024363. Epub 2022 Mar 21.
Background The scope of pericardial involvement in COVID-19 infection is unknown. We aimed to evaluate the prevalence, associates, and clinical impact of pericardial involvement in hospitalized patients with COVID-19. Methods and Results Consecutive patients with COVID-19 underwent clinical and echocardiographic examination, irrespective of clinical indication, within 48 hours as part of a prospective predefined protocol. Protocol included clinical symptoms and signs suggestive of pericarditis, calculation of modified early warning score, ECG and echocardiographic assessment for pericardial effusion, left and right ventricular systolic and diastolic function, and hemodynamics. We identified predictors of mortality and assessed the adjunctive value of pericardial effusion on top of clinical and echocardiographic parameters. The study included 530 patients. Pericardial effusion was found in 75 (14%), but only 17 patients (3.2%) fulfilled the criteria for acute pericarditis. Pericardial effusion was independently associated with modified early warning score, brain natriuretic peptide, and right ventricular function. It was associated with excess mortality (hazard ratio [HR], 2.44; =0.0005) in nonadjusted analysis. In multivariate analysis adjusted for modified early warning score and echocardiographic and hemodynamic parameters, it was marginally associated with mortality (HR, 1.86; =0.06) and improvement in the model fit (=0.07). Combined assessment for pericardial effusion with modified early warning score, left ventricular ejection fraction, and tricuspid annular plane systolic excursion was an independent predictor of outcome (HR, 1.86; =0.02) and improved model fit (=0.02). Conclusions In hospitalized patients with COVID-19, pericardial effusion is prevalent, but rarely attributable to acute pericarditis. It is associated with myocardial dysfunction and mortality. A limited echocardiographic examination, including left ventricular ejection fraction, tricuspid annular plane systolic excursion, and assessment for pericardial effusion, can contribute to outcome prediction.
COVID-19 感染中心包受累的范围尚不清楚。我们旨在评估住院 COVID-19 患者中心包受累的患病率、相关因素和临床影响。
连续的 COVID-19 患者在入院后 48 小时内进行临床和超声心动图检查,无论临床指征如何,这是一项前瞻性预设方案的一部分。方案包括临床症状和体征提示心包炎、改良早期预警评分计算、心电图和超声心动图评估心包积液、左、右心室收缩和舒张功能以及血流动力学。我们确定了死亡的预测因素,并评估了心包积液在心包炎和超声心动图参数之上的附加价值。该研究共纳入 530 例患者。发现心包积液 75 例(14%),但仅 17 例(3.2%)符合急性心包炎的标准。心包积液与改良早期预警评分、脑钠肽和右心室功能独立相关。在心包炎和超声心动图参数调整后的多变量分析中,心包积液与死亡率增加相关(风险比 [HR],2.44;=0.0005)。心包积液与死亡率(HR,1.86;=0.06)和模型拟合改善(=0.07)相关,在调整改良早期预警评分和超声心动图和血流动力学参数后仍具有边缘相关性。心包积液与改良早期预警评分、左心室射血分数和三尖瓣环平面收缩期位移联合评估是预后的独立预测因素(HR,1.86;=0.02),并改善了模型拟合(=0.02)。
在住院 COVID-19 患者中,心包积液很常见,但很少归因于急性心包炎。它与心肌功能障碍和死亡率相关。有限的超声心动图检查,包括左心室射血分数、三尖瓣环平面收缩期位移和心包积液评估,有助于预测结局。